Skip to main content

Table 4 Occurrence of fatal and non-fatal CVD events during follow up according to sero-prevalence of Chlamydia pneumoniae (CP), chlamydia heat shock protein (ch-hsp)60, human heat shock protein (h-hsp)60 and diabetes (DM)

From: Chlamydia pneumoniae, heat shock proteins 60 and risk of secondary cardiovascular events in patients with coronary heart disease under special consideration of diabetes: a prospective study

  N (Column%) Fatal and Non-Fatal CVD-Events During Follow-up N (column %) P-value a
CP – (IgA) (N = 1030)    
negative 645 (62.6) 37 (5.7)  
positive 385 (37.4) 34 (8.8) 0.04
   Patients with DM (N = 199)    
   CP – (IgA)-negative 111 (55.8) 12 (10.8)  
   CP – (IgA)-positive 88 (44.2) 12 (13.6) 0.5
CP – (IgG)    
negative 625 (60.7) 37 (5.9)  
positive 405 (39.3) 34 (8.4) 0.1
   Patients with DM (N = 199)    
   CP – (IgG)-negative 114 (57.3) 12 (10.5)  
   CP – (IgG)-positive 85 (42.7) 12 (14.1) 0.4
Ch-hsp60    
negative 801 (77.8) 54 (6.7)  
positive 228 (22.2) 17 (7.5) 0.7
   Patients with DM (N = 199)    
   Ch-hsp60-negative 158 (79.4) 18 (11.4)  
   Ch-hsp60-positive 41 (20.6) 6 (14.6) 0.6
h-hsp60 (N = 983) b    
negative 900 (91.6) 64 (7.1)  
positive 83 (8.4) 4 (4.8) 0.4
   Patients with DM (N = 199)    
   h-hsp60-negative 186 (93.5) 21 (11.3)  
   h-hsp60-positive 13 (6.5) 3 (23.1) 0.2
  1. a = Log Rank test used only on patients with measured antibody sero-status
  2. b = Only available in 983 CHD patients